28898-02-4

Usage

Uses

Used in Organic Synthesis:
2-FLUORO-2'-NITRODIPHENYLAMINE is used as a building block for the synthesis of complex organic molecules, facilitating the creation of a wide range of chemical compounds with diverse applications.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-FLUORO-2'-NITRODIPHENYLAMINE is utilized as a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Manufacturing:
2-FLUORO-2'-NITRODIPHENYLAMINE is employed as a starting material in the production of agrochemicals, which are essential for crop protection and enhancement of agricultural yields.
Used in Chemical Reactions as a Reagent:
2-FLUORO-2'-NITRODIPHENYLAMINE is used as a reagent in various chemical reactions, aiding in the transformation of other substances and facilitating specific chemical processes.
Used as a Precursor in Synthesis:
2-FLUORO-2'-NITRODIPHENYLAMINE serves as a precursor in the synthesis of a variety of organic compounds, playing a crucial role in the formation of new chemical entities with potential applications in different industries.

InChI:InChI=1/C12H9FN2O2/c13-9-5-1-2-6-10(9)14-11-7-3-4-8-12(11)15(16)17/h1-8,14H

Upstream product

• 12775-96-1 copper 
• 88-74-4 2-nitro-aniline 
• 1493-27-2 ortho-nitrofluorobenzene 
• 348-54-9 2-Fluoroaniline 
• 88-73-3 2-Chloronitrobenzene 
• 348-52-7 1-Fluoro-2-iodobenzene 

Downstream Products

• 28898-03-5 N-(2-fluorophenyl)benzene-1,2-diamine 
• 1429049-13-7 N¹-(2-aminophenyl)-N¹-butyl-N²-(2-fluorophenyl)-N²-methylbenzene-1,2-diamine 
• 1429049-19-3 N-methyl-2-(10-methylphenazin-5(10H)-yl)aniline tosylate 
• 1429049-08-0 N¹-butyl-N²-(2-fluorophenyl)-N²-methyl-N¹-(2-nitrophenyl)benzene-1,2-diamine 
• 1429049-05-7 N¹-(2-fluorophenyl)-N¹,N²-dimethyl-N²-(2-nitrophenyl)benzene-1,2-diamine 
• 1429049-10-4 N¹-(2-aminophenyl)-N²-(2-fluorophenyl)-N¹,N²-dimethylbenzene-1,2-diamine 
• 1429049-03-5 N¹-(2-fluorophenyl)-N¹-methyl-N²-(2-nitrophenyl)benzene-1,2-diamine 
• 908242-59-1 N¹-(2-fluorophenyl)-N¹-methylbenzene-1,2-diamine 
• 1429049-16-0 N-butyl-2-(10-methylphenazin-5(10H)-yl)aniline 
• 1429049-15-9 N-methyl-2-(10-methylphenazin-5(10H)-yl)aniline 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors

Blocking c-Met kinase activity by small-molecule inhibitors has been identified as a promising approach for the treatment of cancers. Herein, we described the design, synthesis, and biological evaluation of a series of 4-phenoxypyridine-based 3-oxo-3,4-dihydroquinoxaline derivatives as c-Met kinase inhibitors. Inhibitory activitives against c-Met kinase evaluation indicated that most of compounds showed excellent c-Met kinase activity in vitro, and IC50 values of ten compounds (23a, 23e, 23f, 23l, 23r, 23s, 23v, 23w, 23x and 23y) were less than 10.00 nM. Notably, three of them (23v, 23w and 23y) showed remarkable potency with IC50 values of 2.31 nM, 1.91 nM and 2.44 nM, respectively, and thus they were more potent than positive control drug foretinib (c-Met, IC50 = 2.53 nM). Cytotoxic evaluation indicated the most promising compound 23w showed remarkable cytotoxicity against A549, H460 and HT-29 cell lines with IC50 values of 1.57 μM, 0.94 μM and 0.65 μM, respectively. Furthermore, the acridine orange/ethidium bromide (AO/EB) staining, cell apoptosis assays by flow cytometry, wound-healing assays and transwell migration assays on HT-29 and/or A549 cells of 23w were performed. Especially compound 23w, which displayed potent antitumor, apoptosis induction and antimetastatic activity, could be used as a promising lead for further development. Meanwhile, their preliminary structure-activity relationships (SARs) were also discussed.

Light-emitting copper compound based on benzimidazole diphosphine ligand and preparation method of light-emitting copper compound

The invention belongs to the technical field of organic complex synthesis, and relates to a light-emitting copper compound based on a benzimidazole diphosphine ligand and a preparation method of the light-emitting copper compound. The molecular formula of the light-emitting copper compound based on the benzimidazole diphosphine ligand is C43H32CuXN2P2, and the structural formula of the light-emitting copper compound based on the benzimidazole diphosphine ligand is shown as a formula I in the specification. The light-emitting copper compound has strong absorption (epsilon> 5 * 10 L.mol . cm ) near 230 nm, and medium-intensity absorption in a range of 280-300nm, the highest luminous quantum efficiency at 293K reaches 71.53% and the longest service life reaches 61.08 microseconds, so that the light-emitting copper compound is an efficient OLED photoluminescent material and can be applied to the field of preparation of OLED luminescent materials.

Synthesis and biological evaluation of novel pyrazole carboxamide with diarylamine-modi?ed scaffold as potent antifungal agents

Twenty-seven novel pyrazole carboxamides with diarylamine-modi?ed scaffold were designed, synthesized and characterized in detail via 1H NMR, 13C NMR, IR and ESI-HRMS. Preliminary bioassays showed that some of the target compounds exhibited good antifungal activity against Rhizoctonia solani, Rhizoctonia cerealis and Sclerotinia sclerotiorum. Among them, compound 9c-7 exhibited the highest antifungal activities against R. solani, R. cerealis and S. sclerotiorum in vitro with IC50 values of 0.013, 1.608 and 1.874?μg/mL, respectively. Notably, compound 9c-7 still presented the highest fungicidal activities against R. solani in vivo with an IC50 value of 22.21?μg/mL. Molecular docking simulation results reveal that compound 9c-7 binds well to the hydrophobic pockets of the receptor protein succinate dehydrogenase. This study suggests that compound 9c-7 could act as a potential fungicide to be used for further optimization.

Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors

A series of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety were synthesized and evaluated for their c-Met kinase inhibitory activity and antiproliferative activity against five cancer cell lines (HT-29, H460, A549, MKN-45 and U87MG) in vitro. Most of the compounds exhibited moderate-to-significant cytotoxicity as compared with foretinib. The most promising compound 41 (with c-Met IC50 value of 0.90?nM) showed remarkable cytotoxicity against HT-29, H460, A549, MKN-45 and U87MG cell lines with IC50 values of 0.06?μM, 0.05?μM, 0.18?μM, 0.023?μM and 0.66?μM, respectively, and thus it was 1.22- to 3.50-fold more potent than foretinib. Their preliminary structure-activity relationships (SARs) studies indicate that electron-withdrawing groups on the terminal phenyl rings are beneficial for improving the antitumor activity.

Synthesis and in silico evaluation of novel compounds for PET-based investigations of the norepinephrine transporter

Since the norepinephrine transporter (NET) is involved in a variety of diseases, the investigation of underlying dysregulation-mechanisms of the norepinephrine (NE) system is of major interest. Based on the previously described highly potent and selective NET ligand 1-(3-(methylamino)-1-phenylpropyl)-3-phenyl-1,3-dihydro-2H-benzimidaz- ol-2-one (Me@APPI), this paper aims at the development of several fluorinated methylaminebased analogs of this compound. The newly synthesized compounds were computationally evaluated for their interactions with the monoamine transporters and represent reference compounds for PET-based investigation of the NET.

Apparent alkyl transfer and phenazine formation via an aryne intermediate

Treatment of chlorotriaryl derivatives 3a and 3d or fluorotriaryl derivatives 3b and 3e with potassium diisopropylamide afforded alkyl-shifted phenazine derivatives 5a/5b, rather than the expected 9-membered triazaorthocyclophane 2a. The phenazine derivatives were isolated in 78-98% yield depending on the halogen and alkyl group present. In the absence of the halogen (chloro or fluoro), the apparent alkyl shift proceeds more slowly and cannot proceed via the intermediacy of the aryne intermediate. Mechanistic possibilities include intramolecular nucleophilic attack on an aryne intermediate leading to a zwitterionic intermediate and alkyl transfer via a 5-endo-tet process, or via a Smiles rearrangement.

Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-Aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3 H)-yl]-1-(methylamino)butan-2- ols (WYE-103231)

Structural modification of a virtual screening hit led to the identification of a new series of 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol- 1(3H)-yl]-1-(methylamino)butan-2-ols which are potent and selective inhibitors of the norepinephrine transporter over both the serotonin and dopamine transporters. One representative compound S-17b (WYE-103231) had low nanomolar hNET potency (IC50 = 1.2 nM) and excellent selectivity for hNET over hSERT (>1600-fold) and hDAT (>600-fold). S-17b additionally had a good pharmacokinetic profile and demonstrated oral efficacy in rat models of ovariectomized-induced thermoregulatory dysfunction and morphine dependent flush as well as the hot plate and spinal nerve ligation (SNL) models of acute and neuropathic pain.

ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE

The present invention is directed to aryl sulfamide derivatives of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

1,5 Benzodiazepine derivatives

1,5-Benzodiazepine derivatives represented by formula (I), salts thereof, and medicines containing the same as the active ingredient: The compounds exhibit excellent gastrin and/or CCK-B receptor antagonism and are useful as remedies for gastric ulcer and gastrointestinal movement disorder.

Novel 1,5-benzodiazepines as CCK-B ligands. Effect of aryl-carbamic substituents at the C-3 position together with halogen substitution on the benzo-fused ring

The synthesis and biological evaluation as potential CCK-B receptor ligands of a number of 1-isopentyl-3-aryloxycarbamoyl-5-aryl-1,5-benzodiazepines substituted with halogen atoms on the benzo-fused ring is here briefly discussed.